Lonza licenses technology to China’s Junshi for experimental COVID-19 drug

Published 6y ago

ZURICH (Reuters) – Lonza Group said on Monday that China’s Junshi Biosciences has licensed the Swiss contract drug manufacturer’s technology to help produce a neutralizing antibody against COVID-19. Lonza said Junshi’s first neutralizing antibody against the n... More »